Cancer vaccine teams up with immune drugs in fight against advanced tumors
NCT ID NCT02955290
Summary
This trial is testing whether combining an experimental cancer vaccine (CIMAvax) with approved immunotherapy drugs (nivolumab or pembrolizumab) is safe and more effective for treating advanced non-small cell lung cancer or squamous head and neck cancer. The study aims to find the best dose and see if the combination helps patients live longer or keeps their cancer from growing. It is for adults with these specific advanced cancers who meet certain health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Good Samaritan Hospital
West Islip, New York, 11795, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
St. Francis Hospital
Roslyn, New York, 11576, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.